A Study of Abiraterone in Combination With SHR3162 in the Treatment of mCRPC

Phase 1 Unknown 39 enrolled Jiangsu HengRui Medicine Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

The aim of this trial is to evaluate the Drug-Drug interaction with Abiraterone combined with SHR3162 in the Metastatic Castration Resistant Prostate Cancer Patients.

Timeline

Start: 2019-09-26
Primary completion: 2023-06
Completion: 2023-06

Publications

Dai T, Xu Z, Wang H, Han W, Zhang D, Tang K, Wang X, Huang J, He C, Zhou X, Zhang D, Yang C. Pharmacokinetics, safety, and efficacy of fuzuloparib in combination with abiraterone acetate and prednisone in patients with metastatic castration-resistant prostate cancer: a phase 1 dose escalation and expansion study. BMC Cancer. 2026 Jun 25. doi: 10.1186/s12885-026-16182-0. Online ahead of print.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Abiraterone acetate	Small molecule	1000 mg	Oral
Subject	Fluzoparib	Small molecule	100 mg	Oral
Subject	Fluzoparib	Small molecule	150 mg	Oral

A Study of Abiraterone in Combination With SHR3162 in the Treatment of mCRPC

Summary

Timeline

Publications

Drugs

Indications